Skip to main navigation
Skip to main content
Compass Pathways - Compassion Navigation Mental Health Pathways logo
  • About us
        • About us

          COMPASS Pathways is a mental health care company. We are dedicated to accelerating patient access to evidence-based innovation in mental health.

        • About us
          • Why we exist
          • Our values
          • Our approach
        • Our team
          • Executive Team
          • Board of Directors
          • Scientific Advisory Network
        • Our stories

          Everyone has a mental health story, be it their own, or that of a friend or loved one. Our people bring their stories, and a wide range of backgrounds and skills to COMPASS.

          Read our stories
  • Our work
        • Our work

          We want to find better ways to support people suffering with mental health challenges, and we believe we’re onto something important.

        • About psilocybin therapy
        • Pipeline
          • Treatment-resistant depression (TRD)
          • Post-traumatic stress disorder (PTSD)
          • Anorexia nervosa
          • Pipeline overview
          • Investigator-initiated studies
        • Therapist training
          • About our therapist training
        • Preclinical research
          • Discovery Center
          • Other research partnerships
        • Digital technologies
        • Our publications and results
          • COMP360 psilocybin in healthy participants
          • COMP360 psilocybin therapy in TRD
          • COMP360 psilocybin therapy in TRD with antidepressants
          • Therapist training: Frontiers in Psychiatry
        • Partnerships and collaborations
          • Centres of Excellence
          • Partnerships
        • Our approach
          • Compassionate use policy
          • Animal welfare
        • COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa

          Multi-centre, double-blind randomised controlled phase 2 trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological treatment option.

          Read more
  • Join us
        • Join us

          Here at COMPASS, we are united by our commitment to improving patient experience and outcomes in mental health care.

        • Join us
          • Working at COMPASS
          • Careers
          • 60 seconds with ...
        • Header with photos of members of the COMPASS team
        • Our team

          Watch our team video to find out who we are and what defines us.

          Find out more
  • News & views
        • News & views

          Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

        • All news & views
          • COMPASS news
          • Our perspectives
          • Our stories
          • Podcast
          • White Paper
          • COMPASS news archive
        • Mock psilocybin therapy session
        • COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine

          Read more about our Phase 2b Study
  • Investors
        • Investors

          We are COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

        • News & events
          • News releases
          • Events
          • Presentations
          • SEC filings & annual reports
          • Our annual review
        • Stock information
          • Stock quote & chart
          • Historical price lookup
          • Analyst Coverage
          • Split history
        • Corporate governance
          • Documents & charters
          • Executive Team
          • Board of Directors
          • Committee composition
          • Annual general meeting
        • Investor resources
          • Shareholder privacy notice
          • FAQs
          • Email alerts and RSS feeds
          • IR contact
        • COMP360 psilocybin therapy in TRD

          We have completed the largest randomised, controlled, double-blind psilocybin therapy study ever done.

          Read more
  • Impact
        • Impact

          We are working to create positive impact by developing transformative therapies for those who are not helped by current treatments, by helping to build the mental health ecosystem of the future, and by acting responsibly as an organisation.

        • Impact
          • Transformative therapies
          • Mental health ecosystem
          • Responsible organisation
        • About us

          We have put a lot of thought into the kind of organisation we want to be, and make every decision with our four values in mind.

          Read more about us
  • LinkedIn
  • Youtube
  • Accessibility
accessibility options Accessibility options
  • High Contrast
  • Greyscale
  • Negative Contrast
  • Readable
  • Reset

SEC filing details

  • Investor home
  • News & events
    • News releases
    • Events
    • Presentations
    • SEC filings & annual reports
    • Our annual review
  • Stock information
    • Stock quote & chart
    • Historical price lookup
    • Analyst coverage
    • Split history
  • Corporate governance
    • Documents & charters
    • Executive Team
    • Board of Directors
    • Committee composition
    • Annual general meeting
  • Investor resources
    • FAQs
    • Shareholder privacy notice
    • Email alerts & RSS feeds
    • IR contact

Document Details

Form
4
Filing Date
February 3, 2023
Document Date
February 2, 2023
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
COMPASS Pathways plc
Issuer
COMPASS PATHWAYS PLC

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
Back to previous page
Print page Email alerts RSS feeds
  • Investor Relations
  • 4

This website is powered by renewable energy

Useful links
  • Contact us
  • About psilocybin therapy
  • About us
  • Join us
  • News & views
Follow us
  • LinkedIn
  • Youtube
Sign up to receive the latest COMPASS news. Subscribe
  • Unsolicited Information Policy
  • Terms
  • Privacy
  • myPathfinder privacy

COMPASS © . All rights reserved.

This site uses functional cookies and external scripts to improve your experience.

More information
Privacy SettingsMore InformationFunctionalStrictly Necessary Cookies

Privacy Settings

This site uses functional cookies and external scripts to improve your experience. Which cookies and scripts are used and how they impact your visit is specified on the left. You may change your settings at any time. Your choices will not impact your visit.

NOTE: These settings will only apply to the browser and device you are currently using.

More Information

If you would like to know more about Cookie Notices and Cookie Consent click here

Functional

These cookies are required for basic site functionality and are therefore always enabled. These include cookies that allow you to be remembered as you explore the site within a single session or, if you request, from session to session. They help make the shopping cart and checkout process possible as well as assist in security issues and conforming to regulations.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not work. These cookies do not store any personal information.

Accept
You are now leaving COMPASS Pathways’ website.

COMPASS does not control and is not responsible for the content on the website you are about to visit. COMPASS is providing this link as a convenience, and this link does not imply COMPASS endorsement of any material on the website you are about to visit. Do you wish to continue?

No Yes